Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere To Conduct Human Trial of BMS Cancer Drug

publication date: Nov 3, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma has partnered with Bristol-Myers Squibb to co-develop a cancer molecule. In return for exclusive China rights to BMS-817378, a small molecule MET/VEGFR-2 inhibitor, Simcere will conduct a first-in-human clinical trial of the drug candidate as a first step toward SFDA approval. Financial details of the partnership were not disclosed. More details....

Stock Symbols: (NYSE: SCR) (NYSE: BMY)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...